Supernus Pharmaceuticals, Inc. · NASDAQ:SUPN

Supernus Pharmaceuticals — Stifel and Rodman & Renshaw Conferences 2012

19 slides from Supernus Pharmaceuticals's conference presentation, September 2012

  1. Slide 1: Stifel and Rodman & Renshaw Conferences

    Slide 1: Stifel and Rodman & Renshaw Conferences

    Stifel and Rodman & Renshaw Conferences Jack A. Khattar, President & CEO September 2012

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the meaning of the federal securities laws. These statements, among other things, relate to Supernus’ business strategy, goals and expec

  3. Slide 3: Company Highlights

    Slide 3: Company Highlights

    Company Highlights • Late stage specialty CNS pharma with robust pipeline • Two product launches in multi-billion dollar epilepsy Emerging market Leader – SPN-804 in 1Q 2013 in CNS – Trokendi™ XR in 3Q 2013 • SPN-810 for Impulsive Aggression in ADHD – Phase IIb data in 4Q 2012 Multiple Value Drivers

  4. Slide 4: 20+ Years Of Successful Product Development

    Slide 4: 20+ Years Of Successful Product Development

    20+ Years Of Successful Product Development Former Division Of Shire All trademarks are the property of their respective owners. 4

  5. Slide 5: Experienced Executive Team

    Slide 5: Experienced Executive Team

    Experienced Executive Team Jack Khattar, MBA Stefan Schwabe, Ph.D, MD President & CEO EVP, R&D , Chief Medical Officer 26 years (Shire, CIMA, Merck, Novartis, Playtex, Kodak) 24 years (Sanofi, Novartis, J&J) Pad Bhatt, Ph.D Woody Bryan, Ph.D SVP Intellectual Property, CSO VP, Business Development 21

  6. Slide 6: Late Stage & Robust Product Pipeline

    Slide 6: Late Stage & Robust Product Pipeline

    Late Stage & Robust Product Pipeline Product Indication Development NDA Launch SPN-804 Epilepsy PDUFA: October 19, 2012 1Q 2013 Trokendi™ XR Epilepsy Tentative FDA Approval 3Q 2013 Impulsive Aggression SPN-810 Phase IIb in ADHD SPN-812 ADHD Phase IIa SPN-809 Depression IND United Therapeutics Partne

  7. Slide 7: Non-Compliance – A Serious Problem In Epilepsy

    Slide 7: Non-Compliance – A Serious Problem In Epilepsy

    Non-Compliance – A Serious Problem In Epilepsy 71% of patients report missing a dose at least once/month 45% reporting seizures after a missed dose Non-compliance leads to breakthrough seizures Serious Quality of Life Issues that cost annually in excess of $26,000 per patient Increased Healthcare Co

  8. Slide 8: Extended-Release AEDs = Significant Patient Benefits

    Slide 8: Extended-Release AEDs = Significant Patient Benefits

    Extended-Release AEDs = Significant Patient Benefits Reduced # of Doses Reduced Side Effects & Reduced Frequency & Improved Tolerability Precise Timing Smooth/Consistent PK ER IR Compliance Higher Effective Doses Reduced Breakthrough Seizures & Reliable Seizure Control ER = extended release IR = imm

  9. Slide 9: SPN-804: Phase III Trial

    Slide 9: SPN-804: Phase III Trial

    SPN-804: Phase III Trial • A multicenter, randomized, double-blind, placebo-controlled study in refractory partial onset epilepsy - 8 countries - 366 adult patients enrolled • Assess efficacy as adjunctive therapy with up to 3 other AEDs • Patients randomized to: - SPN-804 2400 mg/d, 1200 mg/d, or p

  10. Slide 10: SPN-804: Significant Seizure Frequency Reduction

    Slide 10: SPN-804: Significant Seizure Frequency Reduction

    SPN-804: Significant Seizure Frequency Reduction 50 60 45 P=0.006 P=0.003 42.9 50 52.7 40 P=0.078 Reduction in Partial Seizure 38.2 Reduction in Partial Seizure Frequency/28 Days (%) 35 Frequency/28 Days (%) 40 30 P=0.022 28.7 34.5 25 30 20 20 15 10 10 13.3 5 0 0 SPN-804O SPN-804O 2400 mg/d SPN-804O

  11. Slide 11: 55% Reduction In AE Related Discontinuation vs. Trileptal

    Slide 11: 55% Reduction In AE Related Discontinuation vs. Trileptal

    SPN-804 2400mg/d 55% Reduction In AE Related Discontinuation vs. Trileptal® SPN-804 SPN-804 Number (%) of Patients With: 2400 mg/d 1200 mg/d Placebo (n=123) (n=122) (n=121) Any adverse event (AE) 85 (69.1) 69 (56.6) 67 (55.4) Treatment-related AEs 72 (58.5) 53 (43.4) 47 (38.8) Severe AEs 9 (7.3) 11

  12. Slide 12: Improved Side-Effect Profile At Double The Dose Of Trileptal

    Slide 12: Improved Side-Effect Profile At Double The Dose Of Trileptal

    SPN-804 2400mg/d Improved Side-Effect Profile At Double The Dose Of Trileptal® Dizziness* Diplopia Headache Somnolence Vomiting Nausea Fatigue Asthenia 0 10 20 30 40 50 Trileptal 1200 mg/d (n=171) SPN-804O 2400 mg/d (n=123) Based on comparison of SPN-804O Study 301 vs Trileptal PI (adjunctive therap

  13. Slide 13: Trokendi XR: Switch Study To Establish Bioequivalence

    Slide 13: Trokendi XR: Switch Study To Establish Bioequivalence

    Trokendi™ XR : Switch Study To Establish Bioequivalence Design mimics dose switching in actual clinical practice Study Design Topamax ® Trokendi™ XR Screening 200 – 400 mg/d 200 – 400 mg/d Up to 28 Days 2 Weeks Treatment 2 Weeks Treatment • Multicenter, open-label, 3-period conversion study • Patien

  14. Slide 14: Overwhelming Patient Preference For Trokendi XR

    Slide 14: Overwhelming Patient Preference For Trokendi XR

    Overwhelming Patient Preference For Trokendi™ XR Patient Preference (n=61) Impact on Compliance (n=61) 100.0% 100.0% 93.4% 91.8% 80.0% 80.0% 60.0% 60.0% Patients (%) Patients (%) 40.0% 40.0% 20.0% 20.0% 6.6% 8.2% 0.0% 0.0% SPN-538 Topamax Yes No Over 90% of patients Over 90% of patients agreed prefe

  15. Slide 15: A Proven & Efficient Commercial Strategy

    Slide 15: A Proven & Efficient Commercial Strategy

    A Proven & Efficient Commercial Strategy Targeting Conversion of IR Epilepsy Patients to our XR Products • Relatively small population of neurologists • Sales force sized to deliver optimum number of calls to top 5 deciles of prescribing physicians • Synergy from overlap in physician audience betwee

  16. Slide 16: SPN-810: Novel Product For Impulsive Aggression In ADHD

    Slide 16: SPN-810: Novel Product For Impulsive Aggression In ADHD

    SPN-810: Novel Product For Impulsive Aggression In ADHD • Expected to be first product approved to address this serious unmet medical need – Molindone hydrochloride (D1&2, 5HT2A antagonist) • Positive Phase IIa trial showed: – Safety & tolerability in children 6-12 yrs old – Efficacy for aggression

  17. Slide 17: SPN-812: Novel Non-Stimulant For ADHD

    Slide 17: SPN-812: Novel Non-Stimulant For ADHD

    SPN-812: Novel Non-Stimulant For ADHD • Expected to have a better side effect profile – Norepinephrine reuptake inhibitor – NCE for US market • Positive Phase IIa trial showed: – Safety & tolerability in 52 adults – Efficacy with statistical significance vs. placebo* • Developing extended-release pr

  18. Slide 18: Financials

    Slide 18: Financials

    Financials • As of June 2012: – Cash of $76 MM – Venture debt of $28 MM • Expected 2012 annual cash burn of $55 MM – $60 MM • Financing history – $45 MM in Series A in Dec 05/Feb 06 – $157 MM in non-dilutive net proceeds primarily by monetizing royalties – $47.8 MM net proceeds raised in IPO in May

  19. Slide 19: Summary

    Slide 19: Summary

    Summary • 20+ years of successful product development - 6 marketed products and 1 NDA by partners Emerging Leader • Two product launches in multi-billion dollar epilepsy in CNS market – SPN-804 in 1Q 2013 – Trokendi™ XR in 3Q 2013 Multiple Value Drivers • SPN-810 for Impulsive Aggression in ADHD – P

Source: Internet Archive copy of supernus.com

More decks from Supernus Pharmaceuticals, Inc.

All 18 Supernus Pharmaceuticals decks